We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Download Mobile App

World’s First COVID-19 Vaccine to Be Launched by Russia on August 10-12

By HospiMedica International staff writers
Posted on 31 Jul 2020
Print article
Russia is all set to register a coronavirus vaccine by August 10-12, paving the way for what would be the first official approval of an inoculation against COVID-19 in the world, according to a Bloomberg report.

In a recent televised meeting of officials with Russian President Vladimir Putin, the country’s Deputy Prime Minister Tatyana Golikova said that the vaccine was expected to receive conditional registration in August and production was likely to begin in September. The vaccine developed by the Gamalei Institute of Epidemiology and Microbiology (Moscow, Russia) could be approved for civilian use within three to seven days of its registration, said a person familiar with the process to Bloomberg.

Russia’s COVID-19 vaccine is scheduled to enter Phase 3 trials in Russia, Saudi Arabia and the United Arab Emirates. Despite its developers claiming the vaccine to be safe and potentially the first to be administered to the public, there is concern over the absence of published data and its fast paced development. Russian health professionals will be administered the COVID19 vaccine before the completion of its clinical trials, according to the Bloomberg report. Russia is also conducting clinical trials of a second COVID19 vaccine, while two more vaccines are expected to be soon granted permission for testing.

“The key requirements for a vaccine are its proven effectiveness and safety so everything needs to be done very carefully and accurately,” Putin reportedly said at the end of the meeting with officials. “Our confidence in the vaccine must be absolute.”

Related Links:
Gamalei Institute of Epidemiology and Microbiology

Print article



view channel

Hillrom Acquires Bardy Diagnostics to Expand into Ambulatory Cardiac Monitoring Segment

Hillrom (Chicago, IL, USA) has reached a definitive agreement to acquire Bardy Diagnostics, Inc. (BardyDx; Seattle, WA, USA) for a cash consideration of USD 375 million. The acquisition of BardyDx,... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.